Future studies, testing PEG-FUD, optimized for PEG size and dose in models of kidney disease amenable to renal function assessment, will help ascertain whether inhibition of fibrosis associated with specific decrease of fibronectin deposition translates into improved renal function. This evidence concerns the gene FN1 and kidney disorder.